The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | Transforming patient outcomes in myeloma through real-time, SMS-based monitoring of symptoms & QoL
James Berenson, MD, Berenson Cancer Center, West Hollywood, CA, discusses the results of a feasibility study evaluating mQOL, a patient-reported outcome (PRO) platform for monitoring symptoms and quality of life (QoL) in patients with multiple myeloma through real-time, SMS-based reporting. Dr Berenson highlights the platform’s high engagement rate and ease of use, which enabled rapid identification of actionable events and informed clinical decisions to improve patient outcomes. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
